An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat

Journal of Neurochemistry

Volumn 109, Issue 1, 2009, Pages 52-59

  Bukhatwa, Salma ^a   Iravani, Mahmoud M ^a   Zeng, Bai Yun ^a   Cooper, Jonathan D ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopaminergic neurones; Parkinson's disease; Proteasomal inhibitor I; Stereology; Substantia nigra

Indexed keywords

FLUOROGOLD; PROTEASOME INHIBITOR; PROTEASOME INHIBITOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOMETRY; SUBSTANTIA NIGRA;

ANIMALS; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; OLIGOPEPTIDES; RATS; RATS, WISTAR; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 61849135721     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05956.x     Document Type: Article

References (31)

1. Bedford L., Hay D., Devoy A. et al. (2008) Depletion of 26S proteasomes in mouse brain neurones causes neurodegeneration and Lewy-Like inclusions resembling human pale bodies. J. Neurosci. 28, 8189 8198.
2. Bible E., Gupta P., Hofmann S. L. Cooper J. D. (2004) Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 346 359.
3. Bové J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H., Wu D., Kordower J., Petrucelli L. Przedborski S. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60, 260 264.
4. Deller T., Naumann T. Frotscher M. (2000) Retrograde and anterograde tracing combined with transmitter identification and electron microscopy. J. Neurosci. Methods 103, 117 126.
5. Divac I. Mogensen J. (1990) Long-term retrograde labelling of neurons. Brain Res. 524, 339 341.
6. Domesick V. B., Stinus L. Paskevich P. A. (1983) The cytology of dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area of the rat: a light- and electron-microscopic study. Neuroscience 8, 743 765.
7. Fornai F., Lenzi P., Gesi M. et al. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955 8966.
8. Gundersen H. J. Jensen P. H. (1987) The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147, 229 263.
9. Hawlitschka A., Haas S. J. P., Schmitt O., Weiss D. G. Wree A. (2007) Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 1173, 137 144.
10. Hirst S. Ferger B. (2007) Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice. Synapse 62, 85 90.
11. Iravani M. M., Kashefi K., Mander P., Rose S. Jenner P. (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110, 49 58.
12. Iravani M. M., Haddon C. O., Rose S. Jenner P. (2006) 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res. 1067, 256 262.
13. Kordower J., Kanaan N., Chu Y., Babu R., Stansell J., Terpstra B., Sortwell C., Collier K. Collier T. (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60, 264 268.
14. Li X., Fan X., Yang D., Luo G. Le W. (2008) c-Jun N-terminal kinase mediates lactacystein-induced dopamine neuron degeneration. J. Neuropathol. Exp. Neurol. 67, 933 944.
15. Manning-Bog A., Reaney S., Chou V., Johnston L., McCormack A., Johnston J., Langston J. DiMonte D. (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60, 256 260.
16. Mathur B. N., Neely M. D., Dyllick-Brenzinger M., Tandon A. Deutch A. Y. (2007) Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 1168, 83 89.
17. McNaught K. S. Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191 1944.
18. McNaught K. Olanow C. (2006) Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60, 243 247.
19. McNaught K. S., Olanow C. W., Halliwell B., Isacson O. Jenner P. (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2, 589 594.
20. McNaught K. S., Bjorklund L. M., Belizaire R., Isacson O., Jenner P. Olanow C. W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437 1441.
21. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149 162.
22. Mytilineou C., McNaught K. S., Shashidharan P., Yabut J., Baptiste R. J., Parnandi A. Olanow C. W. (2004) Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J. Neural Transm. 111, 1237 1251.
23. Paxinos G. Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
24. Pontikis C. C., Cella C. V., Parihar N., Lim M. J., Chakrabarti S., Mitchison H. M., Mobley W. C., Rezaie P., Pearce D. A. Cooper J. D. (2004) Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231 242.
25. Przedborski S. Vila M. (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N Y Acad. Sci. 991, 189 198.
26. Rideout H. J. Stefanis L. (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci. 21, 223 238.
27. Rideout H. J., Larsen K. E., Sulzer D. Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899 908.
28. Sauer H. Oertel W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401 415.
29. Schapira A., Cleeter M., Muddle J., Workman J., Cooper J. King R. (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60, 253 255.
30. Schmued L. C. Fallon J. H. (1986) Fluoro-gold: a new fluorescent retrograde axonal tracer with numerous unique properties. Brain Res. 377, 147 154.
31. Zeng B. Y., Bukhatwa S., Hikima A., Rose S. Jenner P. (2006) Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 60, 248 252.